Table 2

Multivariable analysis of all-cause mortality for 955 patients after using an inverse probability of treatment-weighted cohort based on propensity scores

ItemIPTW cohortOriginal cohort
P valueAdjusted OR (95% CI)P valueAdjusted OR (95% CI)
Paxlovid vs azvudine0.5671.084 (0.822 to 1.430)0.6251.102 (0.746 to 1.634)
Age<0.0011.029 (1.018 to 1.041)<0.0011.029 (1.013 to 1.045)
Course0.3960.988 (0.959 to 1.016)0.4590.985 (0.945 to 1.025)
One dose of vaccination0.5961.806 (0.122 to 13.161)0.7461.511 (0.065 to 15.385)
Two doses of vaccination0.7601.246 (0.269 to 4.692)0.9750.968 (0.095 to 6.024)
Three doses of vaccination0.6341.156 (0.651 to 2.160)0.9160.957 (0.439 to 2.273)
Immunocompromised status0.3660.857 (0.611 to 1.194)0.3480.797 (0.491 to 1.271)
Steroids<0.0012.119 (1.409 to 3.280)0.0341.838 (0.067 to 3.315)
Tocilizumab<0.0012.933 (1.816 to 4.725)0.0022.999 (1.506 to 5.954)
Baricitinib0.6341.155 (0.626 to 2.055)0.7581.143 (0.468 to 2.591)
Immunoglobulins<0.0012.572 (1.847 to 3.574)<0.0012.768 (1.739 to 4.393)
Bacteria0.0031.683 (1.187 to 2.370)0.0561.606 (0.980 to 2.591)
Candida<0.0011.737 (1.293 to 2.333)0.0081.752 (1.156 to 2.648)
SOFA score on Day 1<0.0011.451 (1.344 to 1.568)<0.0011.444 (1.298 to 1.612)
  • SOFA, Sequential Organ Failure Assessment.